Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 3, 2023 at 07:30 AM.
Here’s what investors need to know about the announcement.
Earnings
Neurocrine Biosciences missed estimated earnings by 492.31%, reporting an EPS of $-0.51 versus an estimate of $0.13.
Revenue was up $109.80 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.1 which was followed by a 1.14% drop in the share price the next day.
Here’s a look at Neurocrine Biosciences’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | 1.14 | 0.80 | 0.59 | 0.34 |
| EPS Actual | 1.24 | 1.08 | 0.84 | 0.30 |
| Revenue Estimate | 409.09M | 376.50M | 341.31M | 303.40M |
| Revenue Actual | 412.00M | 387.90M | 378.20M | 310.60M |
To track all earnings releases for Neurocrine Biosciences visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
